Your browser is no longer supported. Please, upgrade your browser.
Settings
NVO Novo Nordisk A/S daily Stock Chart
NVO [NYSE]
Novo Nordisk A/S
Index- P/E22.77 EPS (ttm)2.55 Insider Own26.40% Shs Outstand1.90B Perf Week5.29%
Market Cap110.17B Forward P/E21.79 EPS next Y2.66 Insider Trans0.00% Shs Float1.25B Perf Month9.77%
Income6.34B PEG2.71 EPS next Q0.57 Inst Own8.10% Short Float0.18% Perf Quarter14.34%
Sales18.62B P/S5.92 EPS this Y10.60% Inst Trans0.48% Short Ratio1.80 Perf Half Y34.92%
Book/sh3.13 P/B18.51 EPS next Y7.69% ROA39.80% Target Price60.40 Perf Year63.10%
Cash/sh1.65 P/C35.02 EPS next 5Y8.40% ROE85.30% 52W Range32.83 - 57.96 Perf YTD7.97%
Dividend0.95 P/FCF24.94 EPS past 5Y20.10% ROI84.70% 52W High-0.14% Beta0.56
Dividend %1.64% Quick Ratio0.90 Sales past 5Y11.00% Gross Margin84.20% 52W Low76.30% ATR0.63
Employees41656 Current Ratio1.30 Sales Q/Q-3.40% Oper. Margin44.30% RSI (14)82.55 Volatility1.02% 0.82%
OptionableYes Debt/Eq0.01 EPS Q/Q2.10% Profit Margin34.10% Rel Volume1.25 Prev Close57.95
ShortableYes LT Debt/Eq0.00 EarningsFeb 01 BMO Payout62.70% Avg Volume1.28M Price57.88
Recom1.00 SMA205.46% SMA509.47% SMA20024.96% Volume853,884 Change-0.12%
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17Upgrade BofA/Merrill Underperform → Neutral
Oct-31-16Downgrade DNB Markets Buy → Hold
Oct-31-16Downgrade Citigroup Buy → Neutral
Oct-28-16Downgrade BofA/Merrill Neutral → Underperform
Sep-23-16Initiated Piper Jaffray Neutral
Sep-13-16Upgrade Exane BNP Paribas Neutral → Outperform
Sep-09-16Downgrade JP Morgan Overweight → Neutral
Sep-01-16Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-31-16Upgrade HSBC Securities Reduce → Hold
Aug-08-16Downgrade BofA/Merrill Buy → Neutral
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Jan-23-18 09:03AM  Reading the Estimates for Novartiss Alcon in 4Q17 Market Realist
07:34AM  Whats Expected of Novartiss Sandoz Segment in 4Q17? Market Realist
Jan-22-18 11:30AM  Behind Novartiss 4Q17 Estimates: Innovative Medicines Market Realist
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
Jan-19-18 08:43AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis Zacks
Jan-18-18 12:33PM  Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip InvestorPlace
07:38AM  Largest Ablynx investor would consider improved Novo Nordisk bid Reuters
Jan-17-18 09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
Jan-16-18 12:06PM  Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade Benzinga
Jan-15-18 09:55AM  Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU Zacks
Jan-12-18 12:25PM  Three Diabetes Clinical Trials to Watch in 2018 GuruFocus.com
07:41AM  Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference Zacks
Jan-11-18 08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
07:35AM  How Is Bioverativs Eloctate Positioned Now? Market Realist
07:33AM  How Is Roches Hemlibra Positioned for 2018? Market Realist
Jan-10-18 02:18PM  Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know Motley Fool
09:39AM  Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes Zacks
Jan-09-18 09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
08:00AM  Ozempic® approved in Canada for the treatment of adults with type 2 diabetes PR Newswire
08:00AM  Ozempic® approved in Canada for the treatment of adults with type 2 diabetes CNW Group
12:57AM  [$$] Belgiums Ablynx Rejects Novo Nordisk Bid The Wall Street Journal
Jan-08-18 01:00PM  Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid Reuters
12:54PM  Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid Reuters
12:52PM  Novo Nordisk revises up offer for Ablynx to $3.1 billion Associated Press
10:45AM  Novo Nordisk Makes Unsolicited Bid for Ablynx TheStreet.com
10:26AM  [$$] Belgium's Ablynx Rejects Novo Nordisk Bid The Wall Street Journal
09:01AM  Ozempic Could Boost Novo Nordisks Revenue Growth in 2018 Market Realist
07:33AM  How Did Novo Nordisks NovoMix and Human Insulin Perform in 2017? Market Realist
07:32AM  In Drug Deals, $3.1 Billion Isn't Exactly Full-Blooded Bloomberg
07:26AM  ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS GlobeNewswire
04:19AM  Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx Reuters
03:58AM  Novo Nordisk submits proposal to buy biopharmaceutical fi... CNBC Videos
01:01AM  Novo Goes Public With $3.1 Billion Bid to Pressure Ablynx Bloomberg
Jan-07-18 09:09AM  5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers Motley Fool
Jan-05-18 10:35AM  How Novo Nordisks Biopharmaceuticals Segment Performed in 3Q17 Market Realist
09:05AM  How Did Novo Nordisks Victoza and Saxendra Perform in 3Q17? Market Realist
07:37AM  How Did Novo Nordisks Modern Insulin Segment Perform in 3Q17? Market Realist
Jan-04-18 06:28PM  3 Large-Cap Pharma Stocks to Watch Out for This New Year Zacks
06:05PM  Novo Nordisks Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018 Market Realist
04:35PM  How Is Novo Nordisks New Generation Insulin Segment Positioned after 3Q17? Market Realist
03:00PM  How Novo Nordisk Performed in 3Q17 Market Realist
Jan-03-18 09:49AM  Can Merck Regain its Mojo in 2018 After an Unimpressive '17? Zacks
03:07AM  5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now Zacks
Jan-02-18 07:58AM  The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S Zacks
05:16AM  Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2017) GlobeNewswire
03:37AM  In pharma space, we like Tecan and Novo Nordisk: Aberdeen... CNBC Videos
Dec-29-17 04:20PM  These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News Investor's Business Daily
Dec-19-17 01:49PM  3 Top Pharmaceutical Dividend Stocks to Buy Now Motley Fool
Dec-18-17 05:35PM  Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion Zacks
Dec-15-17 07:41AM  Novo Nordisk wins EU panel's backing for key diabetes drug Reuters
07:13AM  Novo Nordisk wins EU panel's backing for key diabetes drug Reuters
Dec-14-17 02:00PM  ETFs with exposure to Novo Nordisk A/S : December 14, 2017 Capital Cube
Dec-11-17 08:45AM  Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target Zacks
Dec-08-17 07:40AM  Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz Zacks
07:32AM  How Eli Lillys Endocrinology Drugs Are Performing Market Realist
Dec-06-17 10:30AM  Analysts Recommendations for GlaxoSmithKline in November 2017 Market Realist
09:48AM  Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes Zacks
Dec-05-17 02:54PM  U.S. FDA approves Novo Nordisk diabetes drug Ozempic Reuters
01:01PM  U.S. FDA approves Novo Nordisk diabetes drug Ozempic Reuters
08:51AM  Sanofi's Toujeo Meets Key Objective in Head-to-Head Study Zacks
Nov-30-17 08:34AM  Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates Benzinga
Nov-22-17 04:55AM  IBM is an unloved stock. This fund manager explains why i... CNBC Videos
Nov-21-17 10:46AM  UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs Reuters
08:00AM  Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. CNW Group
06:03AM  MannKind CEO Michael Castagna on What's Ahead for the Biotech Motley Fool
Nov-17-17 09:00AM  The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel Zacks
Nov-16-17 05:35PM  Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk Zacks
Nov-15-17 11:00AM  Diabetes Community Awakens Important Conversation about Hidden Problem: Hypoglycemia PR Newswire
11:00AM  Diabetes Community Awakens Important Conversation about Hidden Problem: Hypoglycemia CNW Group
Nov-14-17 03:55PM  Emerson (EMR) Secures Automation Systems & Services Contract Zacks
01:05PM  Behind Sanofis 3Q17 Revenue Growth Market Realist
09:29AM  Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day Zacks
Nov-09-17 01:00PM  ETFs with exposure to Novo Nordisk A/S : November 9, 2017 Capital Cube
Nov-08-17 11:14AM  "Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support PR Newswire
08:35AM  Novo Nordisk A/S :NVO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
Nov-07-17 04:19PM  Novo Nordisk A/S Slogs Through the Year Motley Fool
Nov-06-17 08:56AM  Foreign Stock Roundup: Alibaba, Sinopec, BP, Novo Nordisk Beat on Earnings Zacks
Nov-01-17 04:39PM  Allergan Soft On Revenue Though Earnings Top; Novo Nordisk Mixed Investor's Business Daily
03:11PM  Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales Zacks
06:04AM  Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018 Reuters
04:23AM  Drugmaker Novo Nordisk warns U.S. legislation could make business difficult Reuters
04:05AM  Novo Nordisk will continue to deliver on 2017 plans, CFO ... CNBC Videos
03:03AM  Diabetes drugmaker Novo Nordisk expects low to mid single-digit growth in 2018 Reuters
02:39AM  Novo Nordisk CFO: Avalanche of obesity, diabetes affect... CNBC Videos
Oct-30-17 09:33AM  The 3 Best Diabetes Stocks to Buy in 2018 Motley Fool
Oct-29-17 10:01PM  Novo Nordisk, Facing Pricing Pressure, Branches Out Beyond Insulin The Wall Street Journal
Oct-26-17 12:49PM  United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat Zacks
12:28PM  Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss Zacks
12:02AM  [$$] Novo Nordisk warns diabetes costs threaten to overwhelm healthcare Financial Times
Oct-20-17 05:36PM  Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics Zacks
04:36PM  Novo Nordisk Stock: Performance in 3Q17 Market Realist
08:47AM  Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling Zacks
Oct-19-17 03:32AM  Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug Reuters
Oct-18-17 05:34PM  Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide PR Newswire
04:59PM  U.S. FDA panel backs approval of Novo Nordisk diabetes drug Reuters
10:17AM  Impax Laboratories and Amneal Pharmaceuticals Agree to Merge Zacks
09:55AM  Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals Zacks
Oct-17-17 03:55PM  Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks Zacks
10:48AM  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study Zacks
10:04AM  Immune Design's Sarcoma Candidate to Enter Phase III in 2018 Zacks
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.